Press release
Incyte Announces Data on Ruxolitinib Cream in Atopic Dermatitis Accepted for Presentation at the Society for Investigative Dermatology (SID) Virtual Meeting 2021
WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (Nasdaq:INCY) today announced that multiple abstracts from its dermatology portfolio highlighting data on
About this update from Incyte Corporation
[{"type":"text","content":" WILMINGTON, Del.--(BUSINESS WIRE)--\nIncyte (Nasdaq:INCY) today announced that multiple abstracts from its dermatology portfolio highlighting data on ruxolitinib cream, a selective JAK1/JAK2 inhibitor designed for topical application, in patients with atopic dermatitis (AD) will be presented at the Society for Investigative Dermatology (SID) Virtual Meeting 2021, held virtually from May 3-8, 2021.\n\n“Atopic dermatitis is a chronic inflammatory skin condition that can have serious impacts on patients’ quality of life,” said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation & AutoImmunity, Incyte. “We are pleased to present data that highlight the potential of ruxolitinib cream as an effective topical treatment for patients with AD at the SID Virtual Meeting and are thankful for the SID’s efforts in hosting this event virtually for the second year to promote ongoing scientific exchange that could lead to improved outcomes for patients.”\n\nKey abstracts from Incyte-sponsored studies include:\n\nePoster Talks\n\nEffects of Ruxolitinib Cream in Patients with Atopic Dermatitis with Head and/or Neck Involvement (Abstract #311. Patient Population Research)\n\nRuxolitinib Cream Rapidly Decreases Skin Pain in Atopic Dermatitis (Abstract #325. Patient Population Research)\n\nItch-Free State in Patients with Atopic Dermatitis Treated with Ruxolitinib Cream (Abstract #313. Patient Population Research)\n\nEfficacy of Ruxolitinib Cream in Adults and Adolescents with Atopic Comorbidities (Abstract #329. Patient Population Research)\n\nePoster Presentations\n\nAtopic Dermatitis: Patient Characteristics and Patient-Reported Outcomes on Topical Therapy (Abstract #333. Patient Population Research)\n\nAll presentations are available on-demand through May 31, 2021. Session details and listings of all presentations are available in the SID meeting program: https://www.sidannualmeeting.org/information/meeting-program-attendee-user-guide/.\n\nAbout Ruxolitinib Cream\n\nRuxolitinib cream is a proprietary formulation of Incyte’s selective JAK1/JAK2 inhibitor ruxolitinib that has been designed for topical application. Ruxolitinib cream is currently in Phase 3 development for the treatment of atopic dermatitis (TRuE-AD) and for the treatment of adolescents and adults with vitiligo (TRuE-V). Incyte has worldwide rights for the development and comme...